MK4280a

A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)

Enquire

Trial overview

Disease

Haematology

Topic

Non Hodgkins lymphoma

Sponsor

MSD

Description

Study details

For detailed information on this trial, please click here

Trial status

Closed for recruitment

Location

Oxford

Priniciple Investigator

Professor Graham Collins

MBBS, MA, MRCP, FRCPath, DPhil

Haematology Consultant